医学
经皮冠状动脉介入治疗
传统PCI
内科学
心肌梗塞
优势比
置信区间
心脏病学
多元分析
人口
中性粒细胞与淋巴细胞比率
淋巴细胞
环境卫生
作者
Murat Uğur,Mehmet Gül,Mehmet Bozbay,Gökhan Çiçek,Hüseyin Uyarel,Bayram Köroğlu,Mahmut Uluganyan,Serkan Aslan,Eyyüp Tusun,Özgür Surgit,Emre Akkaya,Mehmet Eren
出处
期刊:Blood Coagulation & Fibrinolysis
[Ovid Technologies (Wolters Kluwer)]
日期:2014-06-07
卷期号:25 (8): 806-811
被引量:45
标识
DOI:10.1097/mbc.0000000000000150
摘要
The platelet to lymphocyte ratio (PLR) has been investigated as a new predictor for cardiovascular risk. The aim of the present study was to investigate the prognostic role admission PLRat admission in predicting in-hospital and early mortality in patients presenting with ST segment elevation myocardial infarction (STEMI). A total of 639 consecutive patients with STEMI who underwent primary percutaneous coronary intervention (PCI) were included. The study population was divided into tertiles on the basis of PLR values at the admission. A high PLR (N = 213) was defined as a value in the upper third tertile (PLR >174.9) and a low PLR (N = 426) was defined as any value in the lower two tertiles (PLR ≤ 174.9). The patients were followed for clinical outcomes for up to 6 months after discharge. In Kaplan-Meier survival analysis, the rate of 6-month all-cause deaths was 7% in the high PLR group versus 3% in the low PLR group (P = 0.03). In multivariate analyses, a significant association was noted between high PLR levels and the adjusted risk of 6-month all-cause deaths (odds ratio = 2.51, 95% confidence interval = 1.058-5.95; P = 0.03). PLR is a readily available clinical laboratory value associated with 6-month all-cause death in patients with STEMI who undergo primary PCI.
科研通智能强力驱动
Strongly Powered by AbleSci AI